Synopsis: The shares of Medicamen Biotech Ltd jumped 10% in two days following the approval of the EU registration for paracetamol from the Danish Medicines Authority. The clearance opens access to regulated European markets, strengthens its export-led growth strategy, and offers scalable revenue potential from a high-volume drug.
The shares of this company, which is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations and oncology formulations, had its shares in focus after the company announced the EU paracetamol approval.
With the market cap of Rs 522 crore, the shares of Medicamen Biotech Ltd had hit their intraday high at Rs 405, gaining about 10 per cent in the previous two trading sessions. The shares are trading at a PE of 49, whereas their industry PE is at 31.
About the EU approval
Medicamen Biotech’s stock surged as it made an announcement about having obtained EU registration approval for paracetamol from the Danish Medicines Authority in partnership with XGX Pharma in Denmark. This is indeed a major accomplishment because passing stringent approvals from European regulation authorities is considered to be an essential element for access in tightly controlled pharmacy sectors.
In terms of strategy, it is a positive development for Medicamen as it shores up its plan to use exports as a growth driver by gaining access to Europe, which has a higher standard of compliance and entry requirements. Paracetamol is a high-volume drug that offers a scalable platform for Medicamen to either partner or contract-manufacture a solution to gain entry or expand its reach in Europe. The association here is beneficial for Medicamen in terms of visibility.
The approval of the new entity itself provides a future stream of revenue when combined with other drugs in Europe. Although the company has not revealed a revenue effect within the next few years, it creates a future option for revenue generation through regulated exports. This seems to have resulted in a positive market reaction.
Financial highlights and more
The revenue from operations for the company stood at Rs 47.17 crores in Q2 FY26 compared to Q2 FY25 revenue of Rs 44.74 crores, up by about 5 per cent YoY. Similarly, the net profit stood at Rs 2.12 crore in Q2 FY26, up from Rs 91 lakh in Q2 FY25.
Diversified therapy portfolios of Medicamen place the company in a position where it emerges as a consolidated pharmaceutical as well as a life-systems solutions provider. The company’s therapy portfolios cover both the chronic & acute areas, such as oncology solutions, cardiology solutions, CNS solutions & solutions related to diabetology & a wide array of high-volume areas, such as antibiotic solutions & antimalarial solutions, vitamin solutions & pain management solutions. A diverse therapy portfolio implies a well-diversified business model.
The post Pharma stock jumps 10% after receiving approval to sell paracetamol in European markets appeared first on Trade Brains.